MedinCell has launched a COVID-19 research initiative based on its experience to formulate long-acting injectable Ivermectin. Researchers at Monash University in Melbourne, Australia, have published last Friday a study showing that anti-parasitic drug Ivermectin can kill coronavirus in a laboratory setting in under 48 hours. A single treatment is able to effect around 5,000-fold reduction in virus at 48 hours in cell culture. Ivermectin has a long track record of use as a safe and effective drug to treat several parasitic diseases. MedinCell has published data showing that long-acting formulations of Ivermectin can be designed with varying doses and durations with its BEPO® technology, and is already leading a program aiming at developing a 3-Month injectable product to fight malaria. MedinCell has launched a few weeks ago a research initiative on a long-acting injectable formulation of Ivermectin and believes it could have a role to play in COVID-19 management. Future clinical studies will have to confirm the action of Ivermectin on Covid-19 virus, and the potential effectiveness of a long-acting injectable on its prevention and therefore breaking the chain of transmission. In case of positive results, a BEPO® technology-based long-acting injectable Ivermectin offers a rapidly deployable and affordable solution for a global pandemic.